Drug Profile


Alternative Names: AMO 01; BU-4664L; ECO 04601; ECO 4601; TLN 4601

Latest Information Update: 24 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ecopia BioSciences
  • Developer AMO Pharma; BELLUS Health
  • Class Alkaloids; Antineoplastics; Benzodiazepinones; Small molecules
  • Mechanism of Action Apoptosis stimulants; Ras protein inhibitors; TSPO protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fragile X syndrome
  • Discontinued Glioblastoma

Most Recent Events

  • 11 Aug 2016 Discontinued - Phase-II for Glioblastoma in Canada (IV)
  • 11 Aug 2016 Discontinued - Phase-II for Glioblastoma in USA (IV)
  • 08 Jun 2016 Phase-I clinical trials in Fragile X syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top